Odyssey Therapeutics
Update in progressODTX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. Its pipeline includes OD-001, an oral RIPK2 inhibitor in Phase 2a for ulcerative colitis; OD-002, an oral SLC15A4 inhibitor to block TLR7/8/9-driven IRF5 activation; OD-003, a protein therapy to selectively agonize TNFR2 on Tregs; a TSLP/IL-33 bispecific antagonist; an IL-1R-associated kinase 4 scaffolding inhibitor; and an IRF5 inhibitor. Founded 2021, based in Boston.
Company score
- Sentiment
- 0.01
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.07
- Governance
- 0.15
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.03
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!